Cyclazocine

Cyclazocine is a synthetic opioid developed in the 1960s as a potential analgesic and addiction treatment medication. It is a member of the benzomorphan class of opioids and was developed by the pharmaceutical company Eli Lilly.

History

Cyclazocine was first synthesized in the 1960s by researchers at Eli Lilly. It was initially developed as a potential analgesic, but its strong psychedelic effects led to its investigation as a potential treatment for opioid addiction.

Pharmacology

Cyclazocine is a kappa opioid receptor agonist. It also has some activity at the mu opioid receptor, but this is much weaker than its kappa activity. The drug's psychedelic effects are thought to be due to its kappa receptor activity.

Medical uses

Cyclazocine has been investigated for use in treating opioid addiction. However, its strong psychedelic effects and the development of other, more effective treatments have limited its use in this area.

Side effects

The most common side effects of cyclazocine include hallucinations, dizziness, and nausea. These effects are generally more pronounced at higher doses.

See also

• Benzomorphan
• Opioid
• Kappa opioid receptor

References

<references />

• 
  Cyclazocine